LUX-Lung 3 clinical trial

Afatinib vs Chemotherapy as First-Line Treatment in Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Mutation

A randomized, open-label, Phase III study of afatinib* vs chemotherapy as first-line treatment for patients with Stage IIIB or IV adenocarcinoma of the lung harboring an epidermal growth factor receptor (EGFR) activating mutation.

Patients were recruited at centers in Argentina, Australia, Belgium, Brazil, Canada, Chile, France, Germany, Hong Kong, Hungary, Ireland, Italy, Japan, South Korean, Malaysia, Peru, Philippines, Romania, Russia, Taiwan, Thailand, Ukraine, the UK and the US.

Trial CT.gov-Identifier: NCT00949650

Watch Professor Thomas Lynch discuss the LUX-Lung 3 trial in the clip below.

Rate this

Professor Thomas Lynch considers the LUX-Lung 3 trial. Video filmed in 2015.

Patients

Stage IIIB/IV adenocarcinoma of the lung

EGFR mutation-positive

No prior treatment with chemotherapy for advanced/metastatic disease

No prior treatment with EGFR inhibitors

Eastern Cooperative Oncology Group (ECOG) performance status of 0–1

Stable brain metastases at baseline permitted

 

N=345

Randomization 2:1

Afatinib 40 mg Oral once daily
Cisplatin / pemetrexed 75 mg/m² + 500 mg/m² Intravenous, once every 3 weeks for up to 6 cycles

Endpoints

Primary outcome measure:

  • Progression-free survival (PFS) assessed by independent central review

Secondary outcome measures:

  • Overall survival (OS)
  • Objective response rate (ORR)
  • Disease control rate
  • Health-Related quality of life (HRQoL)
  • Pharmacokinetics
  • Safety

Results

PFS by independent review:

In the overall population, median PFS was significantly longer with afatinib at 11.1 months compared with 6.9 months with cisplatin/pemetrexed.

Hazard ratio = 0.58 95% CI = 0.43–0.78
LUX-Lung 3: figure for progression-free survival (PFS) in the overall population

CI, confidence interval; Cis, cisplatin; Pem, pemetrexed; PFS, progression-free survival.

 

Median PFS among those with common EGFR mutations (del19 and L858R) was 13.6 months for afatinib and 6.9 months for cisplatin/pemetrexed.

LUX-Lung 3: figure for progression-free survival (PFS) in patients with common EGFR mutations

CI, confidence interval; Cis, cisplatin; Pem, pemetrexed; PFS, progression-free survival.

OS:

In the overall population, there was no significant OS benefit with afatinib treatment. In a prespecified subgroup analysis of patients with del19 mutation, afatinib demonstrated ≥1 year OS benefit compared with cisplatin/pemetrexed.

Patients with del19 mutations:

LUX-Lung 3: figure for overall survival (OS) in patients with del19 mutations

CI, confidence interval; Cis, cisplatin; Pem, pemetrexed.

Safety:

The most common treatment-related adverse events were:

  • For afatinib:
    • Diarrhea
    • Rash/acne
    • Stomatitis/mucositis
  • For cisplatin/pemetrexed:
    • Nausea
    • Decreased appetite
    • Fatigue

       

Afatinib improved global health status and HRQoL, and delayed time to deterioration for cough and dyspnea, when compared with cisplatin/pemetrexed.

HRQoL:

Compared with cisplatin/pemetrexed, afatinib significantly delayed the time to deterioration of cough and dyspnea. The delayed deterioration time for pain was not statistically significant.

LUX-Lung 3: HRQoL forest plot for time to deterioration in patient symptoms with afatinib vs cis/pem

CI, confidence interval; Cis, cisplatin; Pem, pemetrexed; Q, question; QLQ, Quality of Life Questionnaire.

 

Afatinib also showed significant improvements in global health status (as an indicator of overall HRQoL).

LUX-Lung 3: global health status forest plot for afatinib vs cis/pem

CI, confidence interval; Cis, cisplatin; Pem, pemetrexed; Q, question; QLQ, Quality of Life Questionnaire.

Conclusion

Afatinib significantly prolonged PFS over standard of care chemotherapy. Patients with advanced adenocarcinoma of the lung and EGFR del19 mutation treated with afatinib had a significant OS benefit of more than 1 year compared with cisplatin/pemetrexed chemotherapy.

 

Did you find this information useful?

References

1

Sequist LV, et al. J Clin Oncol 2013;31(27):3327–3334.

2

Yang JC, et al. J Clin Oncol 2013;31(27):3342–3350.

3

Yang JC, et al. Lancet Oncol 2015;16(2):141–151.

4

Clinicaltrials.gov. https://clinicaltrials.gov/ct2/show/NCT00949650 (Accessed: September 2020).

*Afatinib is approved in more than 80 markets including the EU, Japan, Taiwan, and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list please see here. Registration conditions differ internationally; please refer to locally approved prescribing information.

 

© 2020 Boehringer Ingelheim International GmbH. All rights reserved.

 

Page last updated: December 2020